Given that Gal-9 is increasingly recognized as an important target or immune checkpoint in the TME in the era of immunotherapy, further studies investigating the expression of extracellular Gal-9 and its association with cancer prognosis, using methods such as ELISA, would help elucidate this paradoxical observation. This evidence concerns the gene LGALS9 and cancer.